Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: korman

Q&A: Tyler Korman, Michael Heltzen, Damien Perriman
heltzeninvestorvideoperrimankorman
Transcript: Q2 2026 investor update from EXOZAugust 21, 2026
EXOZ gets $2 Million NIH Grant to Advance Cannabinoids for Drug Discovery
heltzenpress releaseinvestormedicinesciencecannabinoidskorman
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug DiscoveryJune 24, 2026
Finding Genius: eXoZymes AI-Enhanced Enzymes & The Future Of Sustainable Manufacturing
press clippingssciencepodcastNCTcannabinoidskorman
Finding Genius podcast: AI enhanced enzymes & the future of sustainable manufacturingMay 12, 2026
GCxN x EXOZ
biofuelpress releasekorman
eXoZymes Announces Graduation from Shell GameChanger™ Accelerator Powered by NLR (GCxN) ProgramMay 7, 2026
100× scale-up of NCT production achieved
heltzenpress releaseinvestornutraceuticalsmedicineNCTkorman
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
CSO, Tyler Korman
talentinvestorvideokorman
Co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, speaks to his new role as CSONovember 13, 2025
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?
videosciencekorman
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?November 11, 2025
ARCHIVE: eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscienceARCHIVEperrimankorman
ARCHIVE: eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
Tyler Korman
investorpress clippingsvideoARCHIVEkorman
ARCHIVE: Slack Capital interview: Tyler Korman, VP of ResearchMay 15, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscienceARCHIVEkorman
ARCHIVE: GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
Previous page
Page 1 of 2
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark